Cabaletta Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-06-01
- Employees
- 103
- Market Cap
- $281.3M
- Website
- http://www.cabalettabio.com
- Introduction
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Interventions
- Biological: CABA-201
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 12
- Registration Number
- NCT06359041
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸UC Davis, Department of Neurology, Sacramento, California, United States
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Conditions
- Systemic SclerosisScleroderma
- Interventions
- Biological: CABA-201
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 12
- Registration Number
- NCT06328777
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- Conditions
- Idiopathic Inflammatory MyopathyDermatomyositisAnti-Synthetase SyndromeImmune-Mediated Necrotizing MyopathyJuvenile DermatomyositisJuvenile PolymyositisJuvenile Idiopathic Inflammatory Myopathy (JIIM)Juvenile Myositis
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 24
- Registration Number
- NCT06154252
- Locations
- 🇺🇸
University of California Irvine - Accepting Adult Patients, Orange, California, United States
🇺🇸Mayo Clinic Florida - Accepting Adult Patients, Jacksonville, Florida, United States
🇺🇸Northwestern Memorial Hospital - Accepting Adult Patients, Chicago, Illinois, United States
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus ErythematosusLupus Nephritis
- Interventions
- Biological: CABA-201
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 12
- Registration Number
- NCT06121297
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Pamplona, Navarra, Spain
🇺🇸UC Davis Health, Sacramento, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis
- Conditions
- MuSK Myasthenia Gravis
- Interventions
- Biological: MuSK-CAART
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 24
- Registration Number
- NCT05451212
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸UC Irvine, Department of Neurology, Orange, California, United States
🇺🇸UC Davis, Department of Neurology, Sacramento, California, United States
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Conditions
- Pemphigus Vulgaris
- Interventions
- Biological: DSG3-CAART or CABA-201
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Cabaletta Bio
- Target Recruit Count
- 55
- Registration Number
- NCT04422912
- Locations
- 🇺🇸
Stanford University, Dept. of Dermatology, Redwood City, California, United States
🇺🇸UC Davis, Dept. of Dermatology, Sacramento, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States